Tianjin Tianyao
About Us
1939
Year
2001
Year
20
+
6
Billion
Tianjin Tianyao Pharmaceuticals Co., Ltd. (hereinafter referred to as Tianjin Tianyao) is a subsidiary of Tianjin Pharmaceutical Group Co., Ltd. (hereinafter referred to as 'Pharmaceutical Group'). Its predecessor was Tianjin Pharmaceutical Factory, founded in 1939, making it a large-scale pharmaceutical enterprise with over 80 years of history. Tianjin Pharmaceutical (formerly known as Tianjin Pharmaceutical) was listed on the Shanghai Stock Exchange in June 2001, with the stock code 600488......
Tianjin Tianyao
About Us
Tianjin Tianyao Pharmaceuticals Co., Ltd. (hereinafter referred to as Tianjin Tianyao) is a subsidiary of Tianjin Pharmaceutical Group Co., Ltd. (hereinafter referred to as 'Pharmaceutical Group'). Its predecessor was Tianjin Pharmaceutical Factory, founded in 1939, making it a large-scale pharmaceutical enterprise with over 80 years of history. Tianjin Pharmaceutical (formerly known as Tianjin Pharmaceutical) was listed on the Shanghai Stock Exchange in June 2001, with the stock code 600488......
1939
Year
2001
Year
20
+
6
Billion
Active Pharmaceutical Ingredient
Export of API
Dexamethasone series
Primarily indicated for connective tissue diseases, including rheumatoid arthritis, systemic lupus erythematosus, rheumatic heart disease, and dermatomyositis.
Prednisone series
Possesses anti-inflammatory, anti-allergic, and anti-toxicity properties, and is used in the treatment of rheumatoid arthritis and systemic lupus erythematosus.
PREV
NEXT
Methylprednisolone series
Mainly used for systemic lupus erythematosus and refractory nephrotic syndrome. It is also an essential medication for preventing organ transplant rejection.
PREV
NEXT
Amino acid series
Glycine serves as an antacid (for gastric hyperacidity), a therapeutic agent for muscular dystrophy, and a detoxifying agent. Lysine hydrochloride is indicated for poor appetite, malnutrition, and impaired brain development in children resulting from lysine deficiency.
PREV
NEXT
Active Pharmaceutical Ingredient
Export of API
Dexamethasone series
Primarily indicated for connective tissue diseases, including rheumatoid arthritis, systemic lupus erythematosus, rheumatic heart disease, and dermatomyositis.
Prednisone series
Possesses anti-inflammatory, anti-allergic, and anti-toxicity properties, and is used in the treatment of rheumatoid arthritis and systemic lupus erythematosus.
Methylprednisolone series
Mainly used for systemic lupus erythematosus and refractory nephrotic syndrome. It is also an essential medication for preventing organ transplant rejection.
Amino acid series
Glycine serves as an antacid (for gastric hyperacidity), a therapeutic agent for muscular dystrophy, and a detoxifying agent. Lysine hydrochloride is indicated for poor appetite, malnutrition, and impaired brain development in children resulting from lysine deficiency.
PREV
NEXT
Global Strategy
Overseas business
The company is actively expanding its overseas business. Through participating in international exhibitions, conducting technical cooperation and carrying out market promotion, it has built a certain reputation in the international market, with sales companies established in the United States and Singapore. Its API products are sold to more than 70 countries and regions across Europe, America and Asia. Leveraging the advantages of its existing ANDA-approved products in the US, the company is driving the market expansion of oral solid and injectable products. While consolidating the European and American markets, it is accelerating the international registration layout of pharmaceutical preparations, continuously strengthening market development in the Belt and Road and RCEP member countries, exploring new blue oceans in international trade, and speeding up its global layout.
International registration
Qualification Certificate
Global Strategy
Overseas business
The company is actively expanding its overseas business. Through participating in international exhibitions, conducting technical cooperation and carrying out market promotion, it has built a certain reputation in the international market, with sales companies established in the United States and Singapore. Its API products are sold to more than 70 countries and regions across Europe, America and Asia. Leveraging the advantages of its existing ANDA-approved products in the US, the company is driving the market expansion of oral solid and injectable products. While consolidating the European and American markets, it is accelerating the international registration layout of pharmaceutical preparations, continuously strengthening market development in the Belt and Road and RCEP member countries, exploring new blue oceans in international trade, and speeding up its global layout.
International registration
Qualification Certificate
News and Information
Company real-time information
-
-
-
Jinyao Pharmaceutical Shines at the 93rd API China
From November 12 to 14, the 93rd China International Pharmaceutical Ingredients/Intermediates/Packaging/Equipment Fair (API China) was successfully held. Xu Hua, Vice President of the Pharmaceutical Group, Secretary of the Party Committee and Chairman of Jinyao Pharmaceutical, Li Shuxiang, Deputy Secretary of the Party Committee and General Manager, and Chen Hong, Deputy General Manager, led representatives from the Active Pharmaceutical Ingredient (API) Sales Center, Manufacturing Center, and o
News and Information
Company real-time information
-
-
-
Jinyao Pharmaceutical Shines at the 93rd API China
From November 12 to 14, the 93rd China International Pharmaceutical Ingredients/Intermediates/Packaging/Equipment Fair (API China) was successfully held. Xu Hua, Vice President of the Pharmaceutical Group, Secretary of the Party Committee and Chairman of Jinyao Pharmaceutical, Li Shuxiang, Deputy Secretary of the Party Committee and General Manager, and Chen Hong, Deputy General Manager, led representatives from the Active Pharmaceutical Ingredient (API) Sales Center, Manufacturing Center, and o
-
Tianjin Pharmaceutical Group's Skin Care Product Family Shines at CDA Annual Meeting
From November 6th to 9th, the 20th Annual Meeting of the Chinese Medical Doctor Association Dermatologists (CDA 2025) was successfully held. Chen Hong, Vice General Manager of Tianjin Pharmaceutical Group and General Manager of Health Technology, along with Sun Hongming, Vice General Manager of Health Technology, led a team to participate in the exhibition. The company's series of dermatological products were showcased at the event, attracting widespread attention. As one of the largest and most
-
Tianjin Pharmaceutical Group showcases its products at CPHI Europe 2025.
From October 28th to 30th, the global pharmaceutical industry's premier event—CPHI Europe—was held at the Frankfurt Exhibition Center in Germany. Chen Hong, Vice General Manager of Tianjin Pharmaceutical Group, led a team specializing in APIs and formulations exports to participate, deeply integrating into the global pharmaceutical industry chain and showcasing the core strength and international flair of Chinese pharmaceutical companies to the world. The team engaged in intensive business negot
-
Tianjin Pharmaceutical Group's skin care product family showcased at the CSD Annual Meeting
From June 26th to 29th, Tianjin Pharmaceutical Group showcased its comprehensive range of dermatological medications at the 30th Annual Meeting of the Chinese Medical Association for Dermatology and Venereology (CSD 2025). The CSD Annual Meeting is the largest annual academic event for dermatologists in my country. During the conference, Tianjin Pharmaceutical Group highlighted its topical preparations, including hydrocortisone butyrate cream (Eucerin), clopidogrel hydroxyquine cream (Keailin),
-
Joining Forces Globally for a New Pharmaceutical Future — Jinyao Pharmaceutical at CPHI Shanghai
From June 24 to 26, the 23rd World Pharmaceutical Ingredients China Exhibition (CPHI China 2025) was grandly held at the Shanghai New International Expo Center. Xu Hua, Vice President of the Pharmaceutical Group, Secretary of the Party Committee and Chairman of Jinyao Pharmaceutical, and Li Shuxiang, Deputy Secretary of the Party Committee and General Manager of Jinyao Pharmaceutical, led the team to participate in the exhibition, comprehensively demonstrating the company’s overall strength. At
-
-
Tianjin Pharmaceutical Group made a brilliant appearance at the 92nd API China.
From May 21st to 23rd, the 92nd China International Pharmaceutical Ingredients Exhibition (API China) was held in Guangzhou. Xu Hua, Vice President of the Pharmaceutical Group, Party Secretary and Chairman of Tianjin Pharmaceutical Group, and Li Shuxiang, Deputy Party Secretary and General Manager of Tianjin Pharmaceutical Group, led a delegation to participate in the exhibition. This year's API China exhibition featured over a thousand companies and attracted more than 50,000 professional visit
-
Health Technology and Jiangxi Huang Qingrenzhan Huashi Pharmacy Reach Strategic Cooperation
Recently, a health technology company and Jiangxi Huang Qingrenzhan Huashi Pharmacy Co., Ltd. (hereinafter referred to as Huang Qingrenzhan Huashi Pharmacy) reached a strategic cooperation agreement. Sun Hongming, Vice General Manager of Health Technology, and Yin Li, General Manager of Huang Qingrenzhan Huashi Pharmacy, attended the strategic cooperation launch ceremony. This cooperation aims to share advantageous resources, expand product channels, optimize health services, and provide consume
-
Mojia Qingning Pills Shine at the 2025 Chongqing Grand Health Industry Expo & 10th Shuangpin Fair
From March 27 to 29, Jinyao Pharmaceutical showcased its product Mojia Qingning Pills at the 2025 Grand Health Industry (Chongqing) Expo and the 10th Shuangpin Fair, where it also received multiple honors. Sun Hongming, Deputy General Manager of Health Technology, led the team to participate in the exhibition. With the theme “Staying the Course · Embracing Innovation,” the 2025 Grand Health Industry Expo / Shuangpin Fair aimed to guide professionals in the pharmaceutical and healthcare sector to
Sales of Active Pharmaceutical Ingredients
API Sales
API Marketing Center - Overseas Sales Division - API Sales Dept.
Tel: +86-022-65277510
Email: tianfa@tjpc.com.cn
Jinyao Pharmaceuticals (Singapore) PTE. LTD.
Tel: +65 6514 0579
Dar Sheng Trade & Technic Development Co. Ltd.
Tel: +1 (973) 218-2536
Sales of Finished Dosage Forms
FDF Sales
API Marketing Center - Overseas Sales Division - FDF Sales Dept.
Tel: +86 13902093969
Email: lizhao@vip.tjpc.com.cn
Hubei Jinyao foreign Trade Department
Tel: 0710-3227740
● Follow us
Official Accounts
Scan and follow us
Copyright © Tianjin Tianyao Pharmaceuticals Co., Ltd. All rights reserved.
版权所有 © 天津天药集团股份有限公司。保留所有权利。
津ICP备2024020218号-1 互联网药品信息备案凭证备案号：2023010016
Copyright © Tianjin Tianyao Pharmaceuticals Co., Ltd. All rights reserved.
Technical Support: jinkuncms This site supports IPV6
